Joseph Schwartz
Stock Analyst at Leerink Partners
(4.17)
# 792
Out of 5,180 analysts
155
Total ratings
36.69%
Success rate
20.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $210 → $215 | $164.86 | +30.41% | 5 | Mar 24, 2026 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.37 | +173.97% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $21.42 | +226.80% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.44 | +0.42% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $69.53 | +130.12% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $11.01 | +27.16% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.90 | +121.48% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $57.24 | +4.82% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.47 | +3.43% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $16.89 | +255.24% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $115 | $55.39 | +107.62% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $36.57 | +140.63% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $22.13 | -32.22% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $19.77 | +1.16% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $7.48 | +60.43% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $29.05 | -3.61% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $31.42 | +27.31% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.45 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $7.38 | +62.60% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.33 | +2,324.24% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $68.75 | -30.18% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $29.45 | -38.88% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $75.13 | -54.75% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $228.24 | -28.58% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.74 | +1,796.55% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.15 | +412.32% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $33.14 | -9.47% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $103.67 | -71.06% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.71 | +601.75% | 2 | Sep 26, 2017 |
Insmed
Mar 24, 2026
Maintains: Outperform
Price Target: $210 → $215
Current: $164.86
Upside: +30.41%
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.37
Upside: +173.97%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $21.42
Upside: +226.80%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.44
Upside: +0.42%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $69.53
Upside: +130.12%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $11.01
Upside: +27.16%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.90
Upside: +121.48%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $57.24
Upside: +4.82%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.47
Upside: +3.43%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $16.89
Upside: +255.24%
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $55.39
Upside: +107.62%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $36.57
Upside: +140.63%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $22.13
Upside: -32.22%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $19.77
Upside: +1.16%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.48
Upside: +60.43%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $29.05
Upside: -3.61%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $31.42
Upside: +27.31%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $3.45
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $7.38
Upside: +62.60%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.33
Upside: +2,324.24%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $68.75
Upside: -30.18%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $29.45
Upside: -38.88%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $75.13
Upside: -54.75%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $228.24
Upside: -28.58%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.74
Upside: +1,796.55%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.15
Upside: +412.32%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $33.14
Upside: -9.47%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $103.67
Upside: -71.06%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.71
Upside: +601.75%